Emerging Opportunity and Destiny of <i>mcr-1</i> - and <i>tet</i> (X4)-Coharboring Plasmids in Escherichia coli

Abstract

Tigecycline and colistin are used as last-resort therapies to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria. However, the emergence of the plasmid-mediated tigecycline resistance gene tet (X4) and the plasmid-mediated colistin resistance gene mcr-1 represents a significant threat to human health.